Always remember that investments can go down as well as up in value, so you could get back less than you put in. A rule of thumb is to hang on to your investments for at least five years to give them the best chance of providing the returns you are hoping for.

Best Shares to Buy Now

Updated On: Sep 8, 2022
Best Shares to Buy Now

We’ve compiled a list of some of the best shares to buy now. These are our top five stocks based on extensive research and analysis.

We select the best stocks with stellar fundamentals and technicals. Scroll down to see how each stock is excelling on a revenue, income and earnings per share basis. Additionally, we include charts to show you the general performance of the stock over a period of time.

We update this page regularly - removing the losers and adding new winners, so be sure to check back at least once every two weeks to discover what stocks we believe are the best to buy now.

DISCLAIMER: Please remember that when you invest, your capital is at risk. We are NOT authorised by the regulators to give you financial advice (or to carry out any regulated financial activity), so we kindly ask that you not take the information on our website, mobile apps, online community or social media pages as financial advice. The information available on our platforms serves as general financial guidance to give you a feel of what is available in the markets. If you believe you need someone qualified to help you make financial decisions such as what to invest in, we strongly recommend you seek advice from a suitably qualified financial adviser. 

Here are our top five best shares to buy now:

1. Cheniere Energy Inc ($LNG)

Company Profile

Cheniere Energy, Inc. (NYSE American: LNG) is a Houston-based energy company primarily engaged in liquefied natural gas (LNG)-related businesses. Cheniere’s vision is to provide clean, secure and affordable energy to the world. Cheniere is committed to responsible and proactive management of its most important ESG impacts, risks and opportunities. Cheniere’s Climate and Sustainability Principles underpin the strategic, collaborative approach across Cheniere’s operations and the entire LNG value chain.

Through its subsidiaries, Cheniere owns and operates two natural gas liquefaction and export facilities - the Sabine Pass LNG Terminal and Corpus Christi LNG Terminal. Cheniere is also engaged in the LNG and natural gas marketing business through its subsidiary, Cheniere Marketing.

Cheniere’s subsidiary, Cheniere Energy Partners, LP (NYSE American: CQP), owns the Sabine Pass LNG Terminal, which has natural gas liquefaction facilities consisting of six operational Trains for a total production capacity of approximately 30 million tonnes per annum (mtpa) of LNG. The Sabine Pass LNG Terminal also has operational regasification facilities that include five LNG storage tanks, vaporisers and two marine berths, with an additional marine berth under construction. Cheniere Partners also owns the Creole Trail Pipeline, a 94-mile pipeline connecting the Sabine Pass LNG Terminal with several large interstate pipelines. As of 30 June 2022, Cheniere owned 100% of the general partner interest and a 48.6% limited partner interest in Cheniere Partners.

The Corpus Christi LNG Terminal currently has three operational Trains for a total production capacity of approximately 15 mtpa of LNG, three LNG storage tanks and two marine berths. Cheniere is constructing an expansion of the Corpus Christi LNG Terminal for seven midscale Trains with an expected total production capacity of over 10 mtpa of LNG.

Financial Summary

  1. For the six months ending 30 June 2022, Cheniere Energy Inc’s revenues more than doubled from $6.11B to $15.49B.
  2. Revenues reflect LNG revenue increase from $5.91B to $15.21B. Other revenues increased from $61M to $142M. Regasification revenues increased by 1% to $136M.
  3. Net loss totalled $124M. 
  4. Net loss reflects ground leases/rental expenses increase of 32% to $391M (expense) and capitalised interest decrease of 62% to $36M (income).

Market Capitalisation

$42.58B

Shares Outstanding

254.1M

Category

Large-cap

Industry

Oil and Gas - Transportation/Pipeline

Headquarters

Houston, TX, USA

Website

https://www.cheniere.com/ 

Current News

  1. 4 August 2022: Cheniere Reports Second Quarter 2022 Results and Raises 2022 Financial Guidance
  2. 26 July 2022: Cheniere and PTT Sign Long-Term LNG Sale and Purchase Agreement

2. Catalyst Pharmaceuticals Inc ($CPRX)

Company Profile

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercialising novel medicines for patients living with rare diseases.

With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.

Catalyst’s new drug application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (“LEMS”) was approved in 2018 by the US Food & Drug Administration (“FDA”), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

The company is also focused on initiating clinical trials of amifampridine in other ultra-rare neuromuscular conditions.

Financial Summary

  1. For the six months ending 30 June 2022, Catalyst Pharmaceuticals Inc’s revenues increased 45% to $96.2M.
  2. Net income increased 76% to $34.9M.
  3. Basic earnings per share (excluding extraordinary items) increased from $0.19 to $0.34.
  4. Revenues reflect a revenue increase of 51% to $96.1M.
  5. Net income benefited from a decrease in research expense of 2% to $6.5M.

Market Capitalisation

$1.44B

Shares Outstanding

102.8M

Category

Small-cap

Industry

Medical - Biomed/Biotech

Headquarters

Coral Gables, FL, USA

Website

https://catalystpharma.com/ 

Current News

  1. 9 August 2022: Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update
  2. 12 July 2022: Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

3. ON Semiconductor Corporation (onsemi) ($ON)

Company Profile

ON Semiconductor Corporation OR onsemi (NASDAQ: ON) is an American semiconductor supplier company that provides intelligent sensing and power solutions.

The Company’s segments include the Power Solutions Group (PSG), the Advanced Solutions Group (ASG) and the Intelligent Sensing Group (ISG). The PSG segment offers a range of analogue, discrete, module and integrated semiconductor products.

The ASG segment designs and develops analogue, mixed-signal, advanced logic, application-specific standard products (ASSPs) and application-specific integrated circuits (ASICs), radio frequency (RF) and integrated power solutions for a base of end-users in different end markets.

The ISG segment designs and develops complementary metal oxide semiconductor (CMOS) image sensors, image signal processors, and single-photon detectors, including silicon photomultipliers (SiPM) and single-photon avalanche diode (SPAD) arrays, as well as actuator drivers for autofocus and image stabilisation for a base of end-users in the different end-markets.

Financial Summary

  • For the six months ended 01 July 2022, ON Semiconductor Corp’s revenues increased 28% to $4.03B.
  • Revenues reflect power solutions group segment increase of 27% to $2.04B, analogue solutions group segment increase of 23% to $1.41B, Hong Kong segment increase of 41% to $1.11B and United States segment increase of 64% to $672.9M.
  • Net income applicable to common stockholders increased from $274M to $987M.
  • Net income benefited from restructuring.

Market Capitalisation

$29.58B

Shares Outstanding

433.2M

Category

Large-cap

Industry

Electronics - Semiconductor Manufacturing

Headquarters

Phoenix, AZ, USA

Website

https://www.onsemi.com/ 

Current News

4. Enphase Energy Inc ($ENPH)

Company Profile

Enphase Energy, Inc. (NASDAQ: ENPH) is a global energy technology company and the world’s leading supplier of microinverter-based solar-plus-storage systems.

The Company delivers smart, easy-to-use solutions that connect solar generation, storage, and energy management on one intelligent platform. Its semiconductor-based microinverter system converts energy at the individual solar module level and brings a system-based high-technology approach to solar energy generation, storage, control, and management.

Financial Summary

  • For the six months ended 30 June 2022, Enphase Energy Inc’s revenues increased 57% to $971.5M.
  • Net income increased 81% to $128.8M. Revenues reflect United States segment increase of 58% to $792.1M and international segment increase of 55% to $179.4M.
  • Net income benefited from G/L on early exiting of lease-related debt decrease from $56.4M (expense) to $0K, and interest expense decrease of 75% to $4.9M (expense).

Market Capitalisation

$39.66B

Shares Outstanding

134.5M

Category

Large-cap

Industry

Energy - Solar

Headquarters

Freemont, CA, USA

Website

https://enphase.com/ 

Current News

5. Evolent Health Inc ($EVH)

Company Profile

Evolent Health, Inc. (NYSE: EVH) delivers proven clinical and administrative solutions to payers and providers that improve whole-person health while making health care simpler and more affordable.

The company’s solutions encompass the total cost of care management, speciality care management and administrative simplification.

Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance’s Population Health Program Accreditation, and is consistently recognised as a top place to work in healthcare in the United States.

Financial Summary

  • For the six months ending 30 June 2022, Evolent Health Inc’s revenues increased 41% to $617M.
  • Revenues reflect clinical solutions segment increase of 51% to $417.8M and Evolent Health Services segment increase of 25% to $200.1M.
  • Net loss before extraordinary items decreased 53% to $9.5M.
  • The reduced net loss reflects loss on repayment of debt decrease from $19.2M (expense) to $0K, Interest expense - Balancing value decrease of 25% to $17.9M (expense).

Market Capitalisation

$3.41B

Shares Outstanding

91.6M

Category

Mid-cap

Industry

Computer Software - Medical

Headquarters

Arlington, VA, USA

Website

https://www.evolenthealth.com/ 

Current News

You might also like 🤓

  1. Best Stocks and Shares ISA
  2. Best Investment Apps
  3. Best Forex Trading Platforms
  4. Best Trading Apps
  5. Best Pension Providers
  6. Best Crypto Exchanges
  7. Compare Investment Platforms
  8. Compare Trading Platforms
  9. Compare Robo Advisors
  10. Investing in the UK (in Your 20s and 30s)


Koody Man with Laptop

Subscribe to The Plug

Every month, we'll send you The Plug - a curation of the best personal finance content in the UK. We share real-life stories, how-to guides, top personal finance news, popular community questions, and tips to help you stay on top of your money.

Thank you! Your submission has been received!
Error: This email cannot be added because it may already be on our list. Please enter a different email address.

Read The Plug